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Secondary bacterial pneumonia frequently
claimed the lives of victims during the devastat-
ing 1918 influenza A virus pandemic. Little is
known about the viral factors contributing to
the lethality of the 1918 pandemic. Here we
show that expression of the viral accessory pro-
tein PB1-F2 enhances inflammation during pri-
mary viral infection of mice and increases both
the frequency and severity of secondary bacte-
rial pneumonia. The priming effect of PB1-F2 on
bacterial pneumonia could be recapitulated in
mice by intranasal delivery of a synthetic pep-
tide derived from the C-terminal portion of the
PB1-F2. Relative to its isogenic parent, an influ-
enza virus engineered to express a PB1-F2 with
coding changes matching the 1918 pandemic
strain was more virulent in mice, induced more
pulmonary immunopathology, and led to more
severe secondary bacterial pneumonia. These
findings help explain both the unparalleled viru-
lence of the 1918 strain and the high incidence
of fatal pneumonia during the pandemic.
INTRODUCTION
Over the past 2 decades, the human toll from influenza has
averaged 200,000 hospitalizations and 36,000 deaths per
year in the United States alone (Thompson et al., 2003,
2004). Few influenza viruses are sufficiently virulent to di-
rectly cause death in humans. Instead, most deaths are
due to an increased physiologic load in an already com-
promised host, or are the outcome of the combined
effects of the viral disease and a secondary bacterial in-
fection (Mote, 1940; McCullers, 2006). Although bacterial
pneumonia during or immediately following influenza is
a significant contributor to morbidity and mortality (Simon-
sen, 1999), the pathogenic interaction between influenza240 Cell Host & Microbe 2, 240–249, October 2007 ª2007 Elseviruses and bacteria is poorly understood. The 1918 in-
fluenza virus was remarkable for its lethality, accounting
for more than 40 million deaths worldwide (Potter, 1998).
This pandemic strain was capable of causing a fatal pri-
mary pneumonia, although most fatal cases were asso-
ciated with secondary bacterial pathogens (Muir and
Wilson, 1919; Stone and Swift, 1919; Abrahams et al.,
1919; McCullers, 2006; Morens and Fauci, 2007). The rea-
sons for this unparalleled virulence and the strong asso-
ciation with secondary bacterial disease are currently
unknown but are the subject of intense scientific scrutiny.
PB1-F2 is a recently described proapoptotic influenza A
virus (IAV) protein not required for viral replication in ovo or
in cultured cells. It is encoded by an alternative reading
frame present in the PB1 gene of nearly all IAV isolates, in-
cluding highly pathogenic avian IAVs that have infected hu-
mans (Chen et al., 2001; Obenauer et al., 2006) and the IAV
whose genetic information was recovered from a victim of
the 1918 pandemic (Taubenberger et al., 2005). PB1-F2
possesses a C-terminal mitochondrial targeting sequence
(MTS) that is predicted to form a positively charged amphi-
pathic helix (Gibbs et al., 2003). PB1-F2 compromises
mitochondrial function and induces apoptosis, probably
through its association with the inner and outer mitochon-
drial membrane transporters ANT3 and VDAC1, respec-
tively (Zamarin et al., 2005). Synthetic full-length PB1-F2
induces cytotoxicity at concentrations of 50 nM or less
when incubated with cells (Chen et al., 2001), possibly by
forming pores that destabilize the plasma membrane
(Chanturiya et al., 2004). PB1-F2 was recently shown to
enhance viral pathogenicity in the mouse IAV infection
model (Zamarin et al., 2006), raising the question of its
effects on the secondary bacterial infections associated
with high levels of influenza morbidity and mortality.
RESULTS
Expression of PB1-F2 Enhances Secondary
Bacterial Pneumonia
We first examined the effect of PB1-F2 expression on in-
duction of secondary bacterial infection in a mouse modelvier Inc.
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1918 PB1-F2 and PneumoniaFigure 1. Secondary Bacterial Pneumo-
nia Following Influenza
(A) Groups of four to six mice infected with ei-
ther WT influenza virus PR8 (WT) or an isogenic
mut virus that does not express PB1-F2 (PB1-
F2) were euthanized 1, 2, 3, 5, and 7 days af-
ter infection for determination of viral lung load.
Groups of six mice infected with either WT or
PB1-F2 were challenged with pneumococ-
cus on day 7 after infection. Weight loss (B)
and survival (C) are plotted until 7 days after
secondary challenge. Error bars represent
standard deviation, and an asterisk denotes
a significant difference (p < 0.05) compared
to the group infected with PB1-F2 virus. (D)
Pictures of anesthetized mice taken 36–48 hr
after bacterial infection with luciferase-ex-
pressing pneumococci show bioluminescence
indicative of pneumonia. The scale on the right
indicates the number of relative light units per
shaded pixel.(McCullers and Bartmess, 2003; McCullers, 2004) utilizing
the mouse-adapted A/Puerto Rico/8/34 (PR8) strain of in-
fluenza (WT) and an isogenic strain (mut) engineered to
greatly reduce PB1-F2 expression (Zamarin et al., 2006).
Groups of six mice were infected with WT or mut PR8
and challenged 7 days later with bioluminescent Strepto-
coccus pneumoniae. Mice infected with the WT and mut
viruses had similar viral lung loads (Figure 1A) and ex-
hibited similar weight loss through the day of pneumo-
coccal infection (Figure 1B; 5.4% versus 2.2% on day 0,
p > 0.1). After bacterial infection (100 CFU), expression
of PB1-F2 was associated with significantly enhanced
weight loss (25.8% versus 2.2% on day 3, p < 0.05),
greater induction of pneumonia as detected by biolumi-
nescence, and higher mortality (5/6 dead versus 1/6
dead following infection with mut PR8; Figures 1A–1C).
When a 10-fold higher dose of bacteria (1000 CFU) was
utilized, 6/6 mice died when WT PR8 was the viral prime,
compared to 5/6 following infection with mut PR8 (p >
0.1). Control mice infected with either virus and then chal-
lenged with PBS instead of bacteria all survived (data not
shown).
Expression of PB1-F2 Enhances
Immunopathology of Secondary
Bacterial Pneumonia
Having established that expression of PB1-F2 in this
model increases the incidence and exacerbates bacterial
pneumonia, we next addressed whether expression of
PB1-F2 influences the pathogenesis of bacterial pneumo-
nia once it has developed. Mice were challenged with
pneumococcus (1000 CFU) 7 days after infection with ei-
ther WT or mut PR8, and bioluminescent imaging was
used to choose pneumonic mice for detailed characteriza-
tion as described (McCullers and Bartmess, 2003; McCul-
lers, 2004). The higher dose of bacteria was used in this
experiment to insure that mice in both groups had pneu-
monia in order that the comparison of the lungs be rele-
vant. Under these conditions, expression of PB1-F2 wasCell Hostnot associated with significant differences in thoracic bac-
terial bioluminescence or bacterial lung titers at either
early (first detection of pneumonia) or late (after 24 hr of
pneumonia) time points during the course of pneumonia
(Figure 2). We did, however detect significant PB1-F2-
associated differences in immunopathology. PB1-F2
expression significantly (p < 0.05) increased numbers of
white blood cells present in bronchoalveolar lavage
(BAL) fluids (BALFs). This difference was due to increases
in the absolute numbers of neutrophils (Figure 3A), macro-
phages (Figure 3B), and T cells (Figure 3C), but not B cells
(Figure 3D). Based on the lack of differences in viral
(Figure 1A) and bacterial (Figure 2) parameters in this com-
parison of mice infected with the WT and mut PR8, it is
unlikely that enhanced viral virulence from expression of
the PR8 PB1-F2 is the sole or most important factor en-
gendering the increased inflammation. However, Zamarin
et al. showed differences in viral lung load in mice at day 6
(but not day 3) using a different pair of viruses based on the
strain WSN (Zamarin et al., 2006) suggesting that this con-
clusion may not hold for all viruses.
This increased influx of leukocytes into the pulmonary
compartment was correlated with histological changes
apparent in the lungs of infected mice. As reported previ-
ously (McCullers and Rehg, 2002), infection with WT PR8
resulted in multiple parenchymal foci of infection charac-
terized by alveolar inflammation, alveolar epithelial cell hy-
pertrophy and hyperplasia, and occasional alveolar necro-
sis and fibrin deposition. Inflammatory cell infiltrates with
lymphocytes, neutrophils, and macrophages were seen,
particularly in perivascular regions. Notably, the degree
of parenchymal inflammation was diminished in the mut
PR8-infected mice infected (mean pathological score of
0.8 ± 0.5 on day 3 compared to 2.3 ± 0.5 in WT-infected
mice) (Figures 3E–3H). Airway involvement in PR8-in-
fected mice was characterized by inflammatory cells in
the lumen and/or mucosa as well as epithelial necrosis
and epithelial hyperplasia. While WT and mut both in-
duced foci of necrosis/apoptosis and sloughing of airway& Microbe 2, 240–249, October 2007 ª2007 Elsevier Inc. 241
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1918 PB1-F2 and Pneumoniaepithelium, expression of PB1-F2 was associated with in-
creased inflammation in the airways (mean pathological
scores of 2.8 ± 0.5 [WT] versus 1.0 ± 0.0 [mut] on day 3).
The inflammatory infiltrate induced by PB1-F2 was domi-
nated by macrophages. Bacterial superinfection of both
groups increased the pathological alterations, viz., inflam-
matory infiltrates, epithelial cell hypertrophy and hyperpla-
sia, necrosis, and fibrin deposition. These changes were
exacerbated by PB1-F2 expression.
C-Terminal PB1-F2 Peptide Primes
for Bacterial Infection
In the context of viral infection, expression of the PB1-F2
protein enhanced secondary bacterial infections. To de-
termine whether this property was mediated by other viral
proteins or was intrinsic to the PB1-F2 itself, we adminis-
tered peptides derived from the amino acid sequence of
PR8 PB1-F2 to mice and then challenged them with bac-
teria 24 hr later. Two peptides were utilized, one from the
C-terminal region of PB1-F2 including the mitochondrial
targeting sequence and one from the N-terminal region
as a control. Mice became ill and lost significant weight
when given the C-terminal peptide but were unaffected
by the N-terminal peptide or PBS (Figure 4A). Following
bacterial challenge, all mice primed with the C-terminal
peptide succumbed within 8 days, while no mice died in
Figure 2. Titers from Mice with Pneumonia
Groups of mice were infected with either PR8 WT (WT) or an isogenic
mut strain of PR8 unable to express PB1-F2 (PB1-F2) and challenged
7 days later with pneumococcus. Four mice per group were assayed
when they developed early pneumonia (>10,000 relative light units
[RLU]/min from the thorax) and late pneumonia (24 hr of visual biolumi-
nescence and >1,000,000 RLU/min from the thorax) for mean flux of
RLU/min (A) and bacterial lung titers (CFU/ml lung homogenate) (B).
There were no significant differences between mice infected with
PR8 WT and PR8 mut at any time point for any measurement (p >
0.1). Error bars indicate the standard deviation of the measurements.242 Cell Host & Microbe 2, 240–249, October 2007 ª2007 Elseveither control group (Figure 4B). Because the C-terminal
peptide is bacteriocidal for pneumococcus in vitro at con-
centrations ranging between 16 and 256 mM (data not
shown), this finding could have been mediated by pep-
tide-induced bacterial death and the subsequent inflam-
matory response. Thus, to determine whether the inflam-
matory changes seen in the BAL were a direct effect of
PB1-F2 or were mediated through an interaction with the
bacteria, mice were given peptides or PBS and then sac-
rificed for collection of BALF 72 hr later. A 2–3 log increase
in neutrophil and macrophage numbers was seen in the
BALF of mice that were given the C-terminal peptide
(Figures 4C and 4D). T cells and B cells were not increased
relative to control groups. Administration of bacteria (100
CFU) in the absence of peptide did not increase the cellu-
larity of the BAL (data not shown). Therefore, the PB1-F2
can elicit inflammation and promote severe bacterial
pneumonia outside the context of the virus, a function
that maps to the C-terminal region of the protein.
The 1918 PB1-F2 Contributes to Virulence
Could the 1918 PB1-F2 have contributed to the pandemic
strain’s unparalleled virulence? To examine this question
we modified the PR8 PB1 gene segment at eight positions
within the PB1-F2 ORF where the PR8 and 1918 pan-
demic strain sequences differ. Thus, a new virus was res-
cued that differs from the PR8 version by seven amino
acid substitutions and a single residue extension to the
COOH terminus of the PB1-F2 protein, recapitulating
differences between the WT and the 1918 PB1-F2. None
of the nonsynonymous mutations in the PB1-F2 reading
frame result in nonsynonymous mutations in the over-
lapping region of the PB1. Expression of the 1918-like
PB1-F2 protein enhanced the growth of the PR8-PB1-
F2(1918) virus in tissue culture compared to WT
(Figure 5A) and significantly increased the mean plaque
size (1.33 ± 0.36 mm) compared to either WT (0.79 ±
0.35 mm) or mut PR8 (0.79 ± 0.20 mm) (Figure 5B; p <
0.001). PR8-PB1-F2(1918) was unable to grow in the
absence of trypsin (data not shown), a characteristic of
the reconstituted 1918 strain (Tumpey et al., 2005). PR8-
PB1-F2(1918) was more virulent than WT in mice
(Figure 6A) and reached significantly higher mean titers 2
days after infection (Figure 6B; p < 0.01). However, this ac-
celerated growth at early time points in mice did not result
in a higher peak titer, and no differences in viral lung load
were present at either 3 or 7 days after infection. We next
examined the cellularity of the BALF of mice infected with
WT PR8, mut PR8, or PR8-PB1-F2(1918) 1, 3, and 7 days
after infection. Expression of 1918 PB1-F2 increased pul-
monary inflammation on day 7 (but not day 1 or day 3) with
increases in absolute numbers of pulmonary neutrophils,
macrophages, and T cells compared to WT and mut
PR8 (Figures 6C–6F).
The 1918 PB1-F2 Primes for Secondary Bacterial
Pneumonia More Efficiently Than WT PR8
We next determined the effect of PB1-F2(1918) expres-
sion on bacterial superinfection. Groups of ten miceier Inc.
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1918 PB1-F2 and PneumoniaFigure 3. Cell Counts from BALF of Sec-
ondarily Infected Mice with Pneumonia
Mice were infected with PR8 WT (WT), an iso-
genic mut strain of PR8 unable to express
PB1-F2 (PB1-F2), or PBS, followed 7 days
later by pneumococcus. Selected mice that
developed early pneumonia (six to ten per
group) were assayed for number of neutrophils
(A), macrophages (B), T cells (C), and B cells (D)
from BALF samples. The 25th–75th percentiles
are represented by the shaded box-plots, with
the horizontal bar indicating the mean value.
Error bars indicate the standard deviation of
the measurements. A double asterisk indicates
a significant difference (p < 0.05) compared to
all other groups, and an asterisk indicates a sig-
nificant difference compared to the mut PR8
group. In a separate experiment, lungs were
taken from mice 3 days after infection with ei-
ther PR8 WT (E and F) or PR8 mut (G and H).
Pictured are representative sections at either
103 (E and G) or 403 (F and H) magnification.
Necrosis of the airway epithelium, manifest as
killed cells with disruptions in the epithelial
layer and deposition of debris, and inflamma-
tory infiltration with neutrophils are more prom-
inent in the mice infected with the WT virus.infected with WT PR8 or PR8-PB1-F2(1918) were chal-
lenged with bacteria 7 days later. Expression of PB1-
F2(1918) significantly enhanced mortality (p < 0.01)
(Figure 7A) and increased bacterial growth (p < 0.01) 1,
2, and 3 days following bacterial challenge (Figure 7B).
Control mice infected with either virus at this dose and
then challenged with PBS instead of bacteria all survivedCell Host(data not shown). Histopathologic examination of pneu-
monic lungs taken from WT PR8-infected mice revealed
changes similar to those observed in earlier experi-
ments described above. Infection with PR8-PB1-F2(1918)
resulted in a severe, purulonecrotic, lobar pneumonia
characterized by diffuse coagulative necrosis of the in-
terstitium, marked pleuritis, and massive neutrophilicFigure 4. Peptide from the C-Terminal
Portion of PB1-F2 Elicits an Inflamma-
tory Response and Primes for Secondary
Bacterial Pneumonia
Groups of five mice were given peptides or PBS
as a control intranasally on day 1, then chal-
lenged with 100 CFU of bacteria 24 hr later.
Weight loss (A) and mortality (B) are compared.
The peptide from the C-terminal region of the
PB1-F2 protein caused more weight loss prior
to and after bacterial challenge (*p < 0.05 by
Student’s t test) and less survival (*p < 0.01 by
log-rank test on the Kaplan-Meier survival
data) than did a peptide from the N-terminal re-
gion or PBS. Groups of five mice were assayed
for number of neutrophils (C) and macrophages
(D) from BALF samples 3 days after exposure to
peptide alone. The 25th–75th percentiles are
represented by the shaded box-plots, with the
horizontal bar indicating the mean value. Error
bars indicate the standard deviation of the mea-
surements. An asterisk indicates a significant
difference (p < 0.05) by ANOVA compared to
both controls at that time point.& Microbe 2, 240–249, October 2007 ª2007 Elsevier Inc. 243
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1918 PB1-F2 and PneumoniaFigure 5. Growth and Plaque Size of a
Virus Expressing the 1918 PB1-F2
An otherwise isogenic virus engineered to ex-
press the PB1-F2 protein from the 1918 pan-
demic strain (1918) was compared to the WT
PR8 strain (WT). (A) HA titer is compared for
a virus expressing the 1918 PB1-F2 to WT
PR8. Error bars indicate standard deviation of
the measurements, and an asterisk indicates
a significant difference at that time point by
the paired Student’s t test (p < 0.05). (B) Plaque
size was measured for a virus expressing the
PB1-F2(1918) compared to WT PR8 (WT) and
a virus that does not express the PB1-F2 pro-
tein (PB1-F2). An asterisk indicates a signifi-
cant difference (p < 0.00001) compared to
both other groups.bronchitis and bronchiolitis (Figures 7C and 7D). Extrava-
sation of lymphocytes and plasma cells was evident peri-
vascularly and along the airways. Compared to the patchy
distribution of consolidated foci seen in the mice prein-
fected with WT PR8, entire lung lobes were diffusely in-
volved in mice infected with PR8-PB1-F2(1918). The find-
ing of necrotic changes in the airways and the prominence
of neutrophils and macrophages resemble the pathology
reported for mice infected with the fully reconstructed
1918 strain (Tumpey et al., 2005), although in the present
instance it is greatly exacerbated by secondary bacterial
infection.
The 1918 PB1-F2 Promotes Cytokine and
Chemokine Release during Secondary
Bacterial Pneumonia
We further characterized the effect of PB1-F2(1918) on the
pathological process by measuring a set of six cytokines244 Cell Host & Microbe 2, 240–249, October 2007 ª2007 Elsand chemokines (TNF-a, IL-1-a, IL-6, IL-10, KC, MIP-1a)
previously implicated in the pathogenesis of secondary
bacterial infections in the mouse model (Smith et al.,
2007). No significant differences were seen in this panel
on day 3 and day 7 after primary infection with WT versus
PR8-PB1-F2(1918) (Figures 8A–8F). Three days after bac-
terial infection (10 days after viral infection), however,
mean values for the entire panel except IL-10 were signif-
icantly elevated in mice infected with PR8 PB1-F2(1918)
versus WT PR8 (Figure 8A–8F).
DISCUSSION
Taken together, our findings indicate that PB1-F2 plays an
important role in promoting lung pathology in both primary
viral infection and secondary bacterial infection. The num-
bers of IAV-associated deaths vary from season to sea-
son, and secondary bacterial pneumonia is a significantFigure 6. Virulence of and Inflammatory
Response to a Virus Expressing the
1918 PB1-F2
An otherwise isogenic virus engineered to ex-
press the PB1-F2 protein from the 1918 pan-
demic strain (1918) was compared to the WT
PR8 strain (WT). (A) Survival of groups of four
mice infected with 500 or 1000 TCID50 of WT
PR8 or PR8-PB1-F2(1918). (B) Viral titers
from lung homogenates taken from groups of
6 to 12 mice at multiple time points after infec-
tion with WT PR8 or PR8-PB1-F2(1918). Error
bars indicate standard deviation of the mea-
surements, and an asterisk indicates a signifi-
cant difference at that time point by ANOVA
compared to the WT PR8. In a separate exper-
iment, mice were infected with PR8 WT, mut,
or PR8-PB1-F2(1918) and were assayed for
number of neutrophils (C), macrophages (D),
T cells (E), and B cells (F) from BALF samples
1, 3, and 7 days after infection. The 25th–75th
percentiles are represented by the shaded
box-plots, with the horizontal bar indicating
the mean value. Error bars indicate the stan-
dard deviation of the measurements. A double
asterisk indicates a significant difference (p <
0.05) by ANOVA compared to the other groups
at that time point.evier Inc.
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1918 PB1-F2 and PneumoniaFigure 7. 1918 PB1-F2 and Secondary
Bacterial Pneumonia
Groups of ten mice were infected with 50
TCID50 of WT PR8 or PR8-PB1-F2(1918) fol-
lowed 7 days later by bacterial challenge. (A)
Survival following bacterial challenge is plot-
ted, and an asterisk indicates a significant dif-
ference in survival by the log-rank test on the
Kaplan-Meier data. (B) Bacterial lung loads
from five mice per group and time point were
determined 24, 48, and 72 hr after bacterial
challenge. The 25th–75th percentiles are rep-
resented by the shaded box-plots, with the
horizontal bar indicating the mean value. Error
bars indicate the standard deviation of the
measurements. An asterisk indicates a signifi-
cant difference (p < 0.05) by ANOVA compared
to WT PR8 at that time point. Lungs were taken
from five mice per group with evidence of
pneumonia by bioluminescence 3 days after
infection with either WT PR8 (data not shown)
or PB8-PB1-F2(1918) (C and D). Pictured are
representative sections at either 103 (C) or
403 (D) magnification. Massive, lobar, coagu-
lative necrosis with pleuritis and leukocytic
infiltration is evident.contributor to this yearly toll (Thompson et al., 2003). Dif-
ferences in viral virulence factors likely contribute to fluc-
tuations in secondary bacterial pneumonia and annual
mortality (Peltola et al., 2005; McCullers, 2006). IAVs are
subtyped by differences in their hemagglutinin (HA) andCell Hostneuraminidase (NA) glycoproteins. Over the last 2 de-
cades, infections with H1N1 strains have caused less mor-
bidity and mortality than H3N2 strains (Thompson et al.,
2003, 2004; Simonsen et al., 2000). Post-1956 H1N1 vi-
ruses possess PB1 gene segments that encode truncatedFigure 8. Cytokines and Chemokines in
Secondary Bacterial Pneumonia
Groups of ten mice were infected with WT PR8
or PR8-PB1-F2(1918) followed 7 days later by
bacterial challenge. Levels of TNF-a (A), IL-1a
(B), IL-6 (C), IL-10 (D), KC (E), and MIP-1a (F)
from lung homogenates taken from mice 3
and 7 days after viral infection (prior to bacterial
challenge) and 72 hr after bacterial challenge
(10 days after viral infection) are presented.
The 25th–75th percentiles are represented by
the shaded box-plots, with the horizontal bar
indicating the mean value. Error bars indicate
the standard deviation of the measurements.
An asterisk indicates a significant difference
by ANOVA compared to the WT PR8 group
(p < 0.05).& Microbe 2, 240–249, October 2007 ª2007 Elsevier Inc. 245
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of a stop codon. Such PB1-F2s lack the MTS required for
induction of apoptosis, which is in the region important for
induction of inflammation in our experiments with synthe-
sized peptides (Gibbs et al., 2003). This defect might con-
tribute to the decreased pathogenicity of contemporary
H1N1 strains and their reduced capacity to promote sec-
ondary bacterial infections (Peltola et al., 2006). The pre-
dicted amino acid sequence of the PB1-F2 from the
1918 strain differs at eight positions from the sequence
of PR8, five of them in the C-terminal region. It is of obvi-
ous interest and importance to correlate genetic variation
in this and other PB1-F2 proteins with alterations in PB1-
F2 function. The enhancing effect of these substitutions on
viral replication, completely unexpected from previous
findings that PB1-F2 knockdown does not effect replica-
tion in vitro (Chen et al., 2001; Zamarin et al., 2006), sug-
gests that PB1-F2 can modify the function of one or
more IAV gene products that are required for viral replica-
tion.
The mechanism by which PB1-F2 facilitates inflamma-
tion and secondary bacterial pneumonia is of prime inter-
est. A synthetic version of PB1-F2 has been shown to be
a potent inducer of cell death (Chen et al., 2001), and a syn-
thetic peptide from the C-terminal region provided a strong
proinflammatory stimulus in mice (Figure 4). In vivo, the
protein may be released from moribund or dead cells
and promote cell death in areas surrounding foci of infec-
tion or in first responder infected mononuclear cells. Re-
lease of cell wall components from pneumococci, such
as lipoteichoic acids and peptidoglycan, along with the
cytotoxin pneumolysin, activates the innate immune sys-
tem through Toll-like receptors 2 and 4, leading to produc-
tion of proinflammatory cytokines (Yoshimura et al., 1999;
Malley et al., 2003; McCullers and Tuomanen, 2001). PB1-
F2-mediated cell death may trigger a positive feedback
cytokine loop, amplified by bacterial superinfection, that
enhances the pulmonary inflammatory response to IAV
leading to the immunopathological death of the host.
This hypothesis builds on earlier work demonstrating
that influenza infection prior to bacterial superinfection
causes a synergistic increase in the cytokine response
with a resultant adverse outcome (Smith et al., 2007),
and treatment of secondary pneumonia by antibiotic-me-
diated lysis of pneumococcus does not reduce mortality
(McCullers, 2004). Recent work from Kash et al. supports
this view, as expression of inflammatory and death recep-
tor genes linked to mitochondrial apoptosis is increased
by infection with the reconstructed 1918 virus (Kash
et al., 2006). Although these effects could not be tied di-
rectly to a specific gene product through analyses using
the full virus, our data suggest that the PB1-F2 is a leading
candidate. However, differences in lung cytokines were
not seen in our experiments until after bacterial challenge,
suggesting that expression of PB1-F2 in the context of the
entire 1918 genome may be necessary for the full impact
on inflammation.
While this model is compelling, the proinflammatory ef-
fect of PB1-F2 may be completely unrelated to its proa-246 Cell Host & Microbe 2, 240–249, October 2007 ª2007 Elsevpoptotic functions. PB1-F2 may be directly recognized
by pattern recognition receptors of the innate immune
system, or serve as a chemoattractant similar to human
b-defensins released from dead cells (Yang et al., 1999).
The predicted homology of the C-terminal cationic helical
domain of PB1-F2 to similar regions of the human b-de-
fensins lends some credence to this theory. The immune
effector cells recruited through this mechanism may con-
tribute to immunopathology while accomplishing their pri-
mary function of clearing the infection. Alternatively, ex-
pression of PB1-F2 may alter the expression or function
of other viral proteins that impact viral pathogenesis. Fur-
ther studies are necessary to investigate these hypothe-
ses in detail.
One intriguing result was the shortened time to peak vi-
ral titer observed both in vitro (Figure 5A) and in vivo in the
virus expressing the 1918-like PB1-F2 (Figure 6B). This
appears to be a unique feature of the 1918-like PB1-F2,
since deletion of PB1-F2 from WT PR8 (data not shown)
or WSN (Zamarin et al., 2006) did not alter viral replication
in vitro. In mice, virulence is not diminished by deletion of
PB1-F2 from WT PR8 (data not shown) or WSN (Zamarin
et al., 2006), and the kinetics of viral infection do not differ
in a PR8 background (Figure 1A). Transfer of the PR8 PB1
gene to a WSN background did reveal differences in viru-
lence and clearance of virus from the lungs of mice, al-
though viral titers did not differ at an early time point
(day 3), and in vitro replication was again not affected
(Zamarin et al., 2006). Thus, it could be postulated that
the accelerated tempo of early lung infection of the virus
expressing the 1918-like PB1-F2 allows the virus to out-
pace innate immune mechanisms of control. This could
contribute to virulence, as has been suggested for PR8
(Grimm et al., 2007), highly pathogenic H5N1 viruses
(Gao et al., 1999), and the 1957 H2N2 pandemic strain
(Legge and Braciale, 2003). While this is an interesting hy-
pothesis to explain the increased virulence of the 1918
strain, it fails to explain the enhancement of bacterial su-
perinfections because this enhancement is seen in both
the WT PR8 knockout model (Figures 1B–1D), where there
are no differences in viral kinetics (Figure 1A), as well as in
the 1918 PB1-F2 model (Figure 6). Several factors suggest
that other mechanisms must be considered for the exac-
erbation of secondary bacterial infections with the 1918
PB1-F2, or at the least that there are both direct and indi-
rect contributions of this protein to the pathogenesis. First,
the differences in cellularity of the BALF (Figures 6C–6E)
were initially detected on day 7, a time when viral titers
(Figure 6B) and lung pathology (data not shown) did not
significantly differ. Second, the enhanced secondary bac-
terial pneumonia and elevated cytokines (Figures 8A–8F)
also occurred after viral lung loads had equalized. Had
the increased tempo of early infection been responsible,
these differences would have been expected to be detect-
able earlier, as was seen in experiments with H5N1 viruses
(Gao et al., 1999). Third, even when WT PR8 was given in
much higher doses, or with much higher doses of bacteria,
it never induced pathological alterations of similar char-
acter and magnitude as PB8-PB1-F2(1918) (data notier Inc.
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1918 PB1-F2 and Pneumoniashown). And finally, topical administration of a peptide de-
rived from the C-terminal end of the PB1-F2 protein reca-
pitulates the effects on bacterial superinfection indepen-
dent of viral infection (Figure 4).
Clearly, much remains to be learned about PB1-F2 and
its contribution to viral virulence. We have demonstrated
here that the protein is proinflammatory, can contribute
to virulence, and facilitates secondary bacterial infections.
The ability of 1918 PB1-F2 to enhance the pathogenicity of
PR8 may only represent the tip of the iceberg of the full
pathogenic potential of this protein when expressed in
its natural context of the complete 1918 strain genome.
Given the importance of IAV as a leading cause of virus-in-
duced morbidity and mortality year in and year out, and its
potential to kill tens of millions in the inevitable pandemic
that may have its genesis in the viruses currently circulat-
ing in southeast Asia, it is imperative to understand the
role of PB1-F2 in IAV pathogenicity and transmission in
humans and animals. Our data help explain why the
1918 pandemic strain was so efficient at supporting bac-
terial pneumonia and reinforce the recent suggestion of
the American Society of Microbiology that nations should




The Mount Sinai strain of mouse-adapted influenza virus A/Puerto
Rico/8/34 (H1N1), hereafter referred to as PR8, was genetically engi-
neered to interfere with PB1-F2 expression by substituting in the
PB1 gene T/ C at position 120 and C/ G at position 153 (altering
the initiating Met to Ser and inserting a stop codon after 11 residues).
Both of the substitutions result in synonymous codons in the PB1 read-
ing frame. This virus and its wild-type parent (provided by Dr. Peter Pal-
ese, Mt. Sinai Medical School, New York, NY) were used in experi-
ments described in the text referring to Figures 1, 2, and 3.
For subsequent experiments, a second set of isogenic viruses were
generated at St. Jude Children’s Research Hospital using PR8 plas-
mids derived from the St. Jude influenza virus repository. Full-length
A/Brevig Mission/1/1918 (H1N1) and PR8 PB1 sequences were
aligned and differences within the PB1-F2 encoding region used for
primer design. Generation of a plasmid coding for the 1918 PB1-F2
within the PR8-PB1 backbone was achieved using QuikChange Site-
Directed Mutagenesis (QIAGEN) at nucleotides coding for the eight
predicted amino acid positions where the sequences differ, changing
these predicted amino acids as follows: R33H, G40D, R60Q, N66S,
I68T, L69P, F71S, and END88W (primer sequences available on re-
quest). The resulting plasmid coded for a PB1 protein identical in pre-
dicted amino acid sequence to the WT PR8 parent. This mutated plas-
mid and the wild-type plasmid were utilized in a 7 + 1 reverse genetics
system to generate recombinant viruses as described (Hoffmann et al.,
2002). The sequence of the PB1 gene of the parental PR8 strain gen-
erated by reverse genetics and used in these studies differs from the
published sequence (NCBI NC-002021) at two positions in the PB1-
F2 ORF, resulting in conservative changes R29K and K59R. These
changes were retained in the PR8-PB1-F2(1918) virus so the viruses
would be completely isogenic other than at positions within the PB1-
F2 where the sequence of PR8 differs from A/Brevig Mission/1/1918.
Mutation at these positions to match the NCBI published sequence
did not change the phenotype of the virus in vitro or in mice (data
not shown).
All viruses were passaged once through MDCK cells, stocks were
grown by a single passage through eggs, and allantoic fluid was storedCell Hosat80C. The resultant viral stocks were sequenced to ensure the de-
sired mutations and no additional inadvertent mutations were present.
Furthermore, they were characterized via TCID50 assay in MDCK cells
and EID50 assay in embryonated hen’s eggs, as well as by HA titer and
determination of the number of plaque-forming units (PFU/ml) in
MDCK cells. Growth was assessed by serial HA titer on four to eight
wells every 4–8 hr for 72 hr in comparison to the WT PR8 parent. The
sequences of all eight gene segments of these viruses were identical
other than the mutations described above in the PB1-F2 ORF.
Bacterial Strains
Streptococcus pneumoniae A66.1, a type 3 encapsulated strain, was
obtained from Dr. Elaine Tuomanen at SJCRH and engineered to ex-
press luciferase (Kevin Francis and Jun Yu, Xenogen Corporation, Al-
ameda, CA). Pneumococci were grown in Todd Hewitt broth (Difco
Laboratories, Detroit, MI) to an OD620 of approximately 0.4, then frozen
at 80C mixed 2:1 with 5% sterile glycerol. The titers of the frozen
stocks were quantitated on tryptic soy agar (Difco Laboratories,
Detroit, MI) supplemented with 3% v/v sheep erythrocytes.
Mice
Six- to eight-week-old female Balb/c mice (Jackson Laboratory, Bar
Harbor, ME) were maintained in a Biosafety Level 2 facility in the Ani-
mal Resource Center at SJCRH. All experimental procedures were ap-
proved by the Animal Care and Use Committee at SJCRH and were
done under general anesthesia with inhaled isoflurane 2.5% (Baxter
Healthcare Corporation, Deerfield, IL).
Infectious Model
Infectious agents were diluted in sterile PBS and administered intrana-
sally in a volume of 100 ml (50 ml per nostril) to anesthetized mice held in
an upright position. Groups of six to ten mice were weighed and fol-
lowed at least daily for illness and mortality. Mice found to be moribund
were euthanized and considered to have died on that day. In experi-
ments comparing WT and mut PR8, influenza virus was given at
a dose of 100 TCID50 per mouse followed 7 days later by pneumococ-
cal challenge with 100 or 1000 CFU per mouse, and mice were fol-
lowed for 21 days. For experiments comparing WT PR8 to PR8-PB1-
F2(1918), influenza virus was given to groups of four mice at a dose
of 50, 100, 500, or 1000 TCID50 per mouse (to determine the dose lethal
for 50% of mice [MLD50]), or to groups of six to ten mice at a dose of 50
TCID50 per mouse either as a sole infection (collection of BALF for cell
counts or lungs for viral titers, histopathology, or cytokines) or followed
7 days later by challenge with 100 CFU of pneumococcus (all assays
following bacterial challenge). This lower dose of 50 TCID50 was to en-
sure a sublethal dose was being used, since some mice died after in-
fection with 100 TCID50 of the PR8-PB1-F2(1918) virus alone. Survival
from secondary bacterial pneumonia comparing the WT PR8 to the
PR8-PB1-F2(1918) virus using 100 TCID50 (and excluding mice that
died from viral infection alone) yielded results similar to those depicted
in Figure 6A (data not shown).
Peptides
Using the predicted amino acid sequence of the PR8 PB1-F2 protein,
peptides from the C-terminal (WLSLRNPILVFLKTRVLKRWRLFSKHE)
and N-terminal (MGQEQDTPWILSTGHISTQK) ends were synthesized
on an Apex 396 multiple organic synthesizer (Aaaptec, Louisville, KY)
and suspended in PBS at a concentration of 1 mM. Mice were given
peptides in a volume of 100 ml intranasally while under light isoflurane
anesthesia.
Imaging of Live Mice
Mice were infected with a strain of pneumococcus A66.1 engineered
to express luciferase (Kevin Francis and Jun Yu, Xenogen Corporation,
Alameda, CA). They were then imaged for 60 s using an IVIS CCD cam-
era (Xenogen Corporation, Alameda, CA) 24, 48, and 72 hr after pneu-
mococcal challenge. Total photon emission from selected and defined
areas within the images of each mouse was quantified using thet & Microbe 2, 240–249, October 2007 ª2007 Elsevier Inc. 247
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1918 PB1-F2 and PneumoniaLivingImage software package (Xenogen Corporation, Alameda, CA)
as described (Francis et al., 2001) and expressed as the flux of relative
light units per minute. Pneumonia was defined as visible biolumines-
cence within the thorax and detection of a flux of >20,000 relative light
units (RLU) per minute. Pneumonia was designated ‘‘early’’ when less
than 13 105 RLU/min were present on the initial measurement. Pneu-
monia was designated ‘‘late’’ when it had been present for at least 24
hr and more than 13 106 RLU/min were present on the final measure-
ment. These definitions were developed and validated so that relevant
comparisons could be made between mice at similar stages of the
pneumonic process, avoiding the problem of comparing mice with
large bacterial loads to those with small bacterial loads that is common
to many models of bacterial pneumonia (Smith et al., 2007).
Histopathologic Examination
Lungs were removed immediately following euthanasia, inflated, and
fixed in 10% neutral buffered formalin overnight. The lungs were pro-
cessed routinely, embedded in paraffin, sectioned at 5 mm, stained
with hematoxylin and eosin, and examined microscopically for histo-
pathologic alterations. The pulmonary system was divided into the fol-
lowing segments, bronchi, bronchioles, interstitium, and pleura. Each
segment was assigned a grade 0–3 based on the histologic character
of the lesions. A score of 1 was given to mild findings including minimal
infiltrates of lymphocytes and plasma cells around airways and ves-
sels, minimal epithelial hyperplasia, minimal leukocyte infiltration of al-
veolar spaces, and <10% of the lung affected. A score of 2 was given
for moderate findings including moderate infiltrates of lymphocytes
and plasma cells around airways and vessels, moderate epithelial hy-
perplasia with focal necrosis, focally extensive infiltration of the alveo-
lar spaces by leukocytes with some consolidation, focal pleuritis, and
>10% but <30% of the lung affected. A score of 3 was given for more
severe findings including extensive necrosis of airway epithelium and
the interstitium, extensive leukocyte infiltration and consolidation, se-
vere pleuritis, and lobar involvement. Grading and description of
pathology were performed by an experienced veterinary pathologist
blinded to the composition of the groups (K.L.B.).
BAL for Cell Counts
Following euthanasia by CO2 inhalation, the trachea was exposed and
cannulated with an 18 gauge plastic catheter (BD Insyte, Becton Dick-
inson, Sandy, UT). Lungs were lavaged thrice with 1 ml of cold, sterile
PBS. The number of white blood cells (WBC) per ml of the resulting
suspension was then determined on a Hemavet 3700 (Drew Scientific,
Dallas, TX) using a 100 ml aliquot. Flow cytometry (LSRII, Becton Dick-
inson, San Jose, CA) was performed on the BALF suspension via stain-
ing (1 ml/106 cells) with MHCII(FITC)/CD11b(PE)/B220-CD3e(PeCy-7)/
Gr1(APC)/CD11c(APC Cy-7)/SA-APC-Cy7 (Becton Dickinson, San
Jose, CA). Viable cells were gated (DAPI), and the proportions of T
cells (MHCII, within lymphocyte [FSClow, B220+, CD3+] region), B
cells (MHCII+, within lymphocyte region), neutrophils (Gr1high, MHCII
within nonlymphocyte region), macrophages (CD11c+, CD11b+,
MHCII, within the nonlymphocyte region), and dendritic cells
(CD11c+, CD11b+, MHCII+, within nonlymphocyte region) were as-
sessed. Analysis of BALF cell composition was based upon the pro-
portion of viable events analyzed by flow cytometry as related to the
number of WBC/ml.
Measurement of Cytokines and Chemokines
Lung homogenates were centrifuged at 10,000 3 g for 5 min and the
supernatants frozen. The concentrations of interleukins (IL)-1a, IL-6,
IL-10, and chemokines KC, macrophage inflammatory (MIP)-1a, and
tumor necrosis factor (TNF)-a were measured in lungs by using the
‘‘mouse 18-plex’’ cytokine assay (Bio-Rad Laboratories, Hercules,
CA) read on a Luminex 100 reader (Luminex Corp., Austin, TX) accord-
ing to the manufacturer’s instructions. Samples were diluted 1:4 and
run in duplicate in all assays with appropriate internal controls.248 Cell Host & Microbe 2, 240–249, October 2007 ª2007 ElseStatistical Analysis
Comparison of survival between groups of mice was done with the log-
rank chi-square test on the Kaplan-Meier survival data. Comparison of
viral or bacterial lung titers, cell counts in BALF, or cytokine and che-
mokine levels between groups was done using analysis of variance
(ANOVA). Comparison of weight loss between groups of mice was
done using the Student’s t test for pairwise comparisons and ANOVA
for multiple comparisons. A p value of <0.05 was considered signifi-
cant for these comparisons. SigmaStat for Windows (SysStat Soft-
ware, Inc., V 3.11) was utilized for all statistical analyses.
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